melanoma
Industry
First and only FDA-approved orally administered microbiota-based therapeutic, validating Seres’ microbiome platform –
Industry
The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to…
Industry
The bacterial strains in MB097 were identified by analysing the microbiome of patients in multiple studies of ICIs in melanoma.